AceLink Therapeutics

Founded in 2019 with headquarters in Newark, CA, AceLink Therapeutics is an innovative biopharma startup focusing  on developing safe and effective medicines to address human genetic diseases, including many rare conditions with high unmet needs. The company’s initial focus is on novel therapeutics for genetically associated kidney disorders, such as autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and Fabry disease.